CTRI/2010/091/000255进行中（未招募）3 期
An Open Label, Randomised, Parallel Group, Multi-centre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks with ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women with Oestrogen Receptor Positive Advanced Breast Cancer
AstraZeneca KK Osaka Japan0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Female more or equal 20 years and pre-menopausal.Pre-menopausal defined as 1) last menses within 1 year of randomisation, and 2)
- •E2 more or equal 10 pg/mL and FSH less or equal 30 mIU/mL within 4 weeks of randomisation.
- •For patients who have had a hysterectomy, it is acceptable to meet only
- •-Hormone sensitivity (ER positive)
- •of primary or secondary tumour tissue.
- •-Histological/cytological confirmation
- •of breast cancer and are candidates to receive hormonal therapy as therapy for advanced breast cancer.
排除标准
- •?Patients who have received tamoxifen or other hormonal therapies as adjuvant therapy for breast cancer within 24 weeks before randomisation and/or who have received prior treatment with hormonal therapies for advanced breast cancer
- •?Patients who have received LHRHa as adjuvant therapy for breast cancer within 48 weeks before randomisation
- •?Patients who have relapsed during adjuvant hormonal therapy or within 48 weeks after completion of adjuvant hormonal therapy and/or patients who have relapsed during adjuant chemotherapy or within 24 weeks after completion of adjuant chemotherapy.
研究者
相似试验
进行中（未招募）
不适用
An Open Label, Randomised, Parallel Group, Multicentre Study toCompare ZOLADEX™ 10.8 mg Given Every 12 Weeks with ZOLADEX3.6 mg Given Every 4 Weeks in Pre-menopausal Women with OestrogenReceptor Positive Advanced Breast CancerEUCTR2005-004001-29-CZAstraZeneca AB260
未知
3 期
An Open Label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast CancerBreast CancerJPRN-jRCT2080221070AstraZeneca
进行中（未招募）
不适用
evetiracetam versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset SeizuresEUCTR2014-004402-15-Outside-EU/EEACB Korea Co.,Ltd.340
已完成
3 期
A comparative study of Insulin Aspart (manufactured by BioGenomics Ltd) with Insulin Aspart (NovoRapid) in patients of Type 2 Diabetes Mellitus.CTRI/2019/04/018455BioGenomics Limited320
招募中
3 期
A large study in kids from birth to 18 years of age that have a documented clot in their lung or limbs, to test a new drug (edoxaban) used for treatment or the prevention of recurrent clots in your body.CTRI/2019/04/018361Daiichi Sankyo